genetically engineered to contain on the bacterial chromosome a jellyfish gene that encodes for the protein called Green Fluorescent Protein (encoded by the gfp gene). There are variants of this gfp gene that encode Gfp proteins having different excitation and emission wavelengths, half-life, and which are controlled by various promoters (promoter is the regulatory region of a gene that controls expression of the gene). Your intention is to use the GMO as a tracer organism for spiking suspected pollution sources.
Once the GMO tracer has been designed, you need to identify a detection and quantification method that will be sufficient to determine whether the tracer GMO is present in a nearby surface water system, and if so, how many GMO cells are present. The introduced gene will change both the organism's genotype and (under many circumstances) phenotype, hence your detection method could target the presence of the gfp gene DNA sequence, or of the fluorescent Gfp protein the gfp gene encodes. There are at least four methods that might work:
(1) Samples could be plated on agar and allowed to grown up into visible colonies; (2) Samples could be subjected to PCR (polymerase chain reaction); (3) Samples could be subjected to FISH (fluorescent in situ hybridization); (4) or samples could be passed through a fluorescence activated cell sorter (FACS) could be used. For the PCR method, there are also multiple means of determining if amplified product has been made (i.e. visualization on a gel or one of multiple hybridization-based methods).
Task:
Your task is to assess and compare these methods as candidates for detection and quantification of your GMO in stream water and select a method that best meets the needs of PBL 3 this project. Consider the capabilities, strengths and weaknesses of the test detection and quantification methods with respect to the characteristics of the organism you are trying to detect and the way you are planning to use the organism. Among other selection criteria, you should include sensitivity and specificity of detection.
-Recognize that many methods, including all those that are DNA-based, will not necessarily differentiate between living and dead bacteria.
-Furthermore, living bacteria can exist in a culturable form or a viable but nonculturable form (VBNC). Recognize that phenotypic-based methods presume the protein will be present.
Resources / Readings:

Books:
Web sites:
Wikipedia. Note: Wikipedia is a good source of information but should not be used as a primary reference. Your team should present a final written report targeted for your supervisors, who are administrators who know little about biology. The report should describe the purpose of your investigation, the desired attributes of an optimal detection and quantification method, the methods you evaluated, and the method you recommend to use based on your selection criteria. If your recommended method still falls short in some areas, you should discuss that as well.
As a minimum, your report should be presented using the section headings shown below. You may add additional sections or sub-headings and include other information as you deem necessary. Grading:
85%
Report grading is based upon: a) rationale used in decision making, including selection criteria used, b) choice and use of information sources, and c) clarity of writing, including explanation of rationale and selection criteria used in decision making.
10%
Peer evaluations 5% Class participation (in-class, on-line discussion board)
Discussion Questions:
1) What additional information (about the methods) would have allowed you to make a more definitive choice?
2) There isn't consensus among scientists on which of these four methods is best. Why do you think this is true?
3) When would someone not need a MST method that has a 100% predictive value (see background paragraph)? 4) What are the three most common reasons why the public expressed concern over a GMO release? What are the three most scientifically-based, valid reasons for concern over a GMO release? Why are these lists different? 5) How would your method ranking have changed if the problem scenario goal was changed from detecting a released GMO to detecting the presence of pathogenic bacteria in food products?
NOTE: Every student should email the course instructors any questions they would like answers to or problems they are having in developing their solution strategy, and how they PBL 6 would like the instructors to help (e.g., cover certain material in the next class, suggest a resource to obtain certain information).
MODULE #2 -Genetic Testing
Background "Rabbi, who sinned, this man or his parents, causing him to be born blind?" (John 9:2).
Scientific advancements in the past 20 years would now allow us to answer this 2000 year-old question.
There is a genetic component to almost every disease, and in some cases a single gene determines whether the gene carrier will contract a disease. Usually, the genetic locus responsible for a "genetic disease" is an altered (or mutated) form of a gene that is found in all individuals. For example, in Huntington's disease the length of a tri-nucleotide repeat (sequence "CAG") located at the HTT gene determines disease status. If there are fewer than 35 contiguous copies of this repeat at the gene, the individual is unaffected; if there are more than 40 copies, the individual is affected. For cystic fibrosis, many types of DNA changes to the CFTR gene can result in disease, but about 70% of mutations in CF patients result from a three-base deletion, resulting in loss of one amino acid from the wild-type protein (this mutation [abbreviated "F"] located at the 508 th amino acid position on the protein Most diseases/traits are not caused by a single, simple DNA change having a high penetrance.
In many cases, a genotype is found to have a less than 100% correlation with a certain phenotype. For example, having a mutation in either the BRCA1 or BRCA2 gene means your chance of acquiring breast cancer is ~80% (approximately 5% of breast cancers are attributed to heredity) and your chance of acquiring ovarian cancer is ~20%. In other types of disease/traits/cancers, the correlation between genotype and phenotype is much lower. This PBL 9
makes finding the genetic link more difficult; it also makes knowing how to use the information less clear.
In the past (pre-2000) , investigators would focus on a given disease/trait (i.e. phenotype) and work backwards to identify the responsible gene. This would often be done by identifying proteins involved in the wild type phenotype. The sequence of the gene(s) encoding the protein(s) would be obtained and then compared between normal and affected individuals. If using an animal model, the gene from a healthy animal may be intentionally mutated and introduced into the animal to see if it induced the trait. Once the responsible gene was identified, it would be further studied. Today, this approach is still used, but additional tools are available, based upon knowing the sequence of the entire animal's genome, including that of humans.
The human genome contains approximately 3.3 billion base pairs (per haploid). Within these 3.3 billion base pairs, there are approximately 10 million locations in which humans differ from one another. That is, of the 3.3 billion base pairs that comprise the haploid genome, all humans are identical at 3.29 billion of those base pairs. Of those 10 million remaining locations, the difference between people resides in being able to find more than one of the four different bases (e.g., A, T, C or G). Expressed another way, there are 10 million single-nucleotide polymorphisms (SNPs) in the human genome.
Once the number and location of SNPs was determined, the strategy for identify links between genes and diseases changed. Now, instead of looking for which of 3.3 billion base pairs may PBL 10 be responsible for causing a disease, researchers need focus only on those 10 million SNPs.
Furthermore, SNPs can be used for more than identifying what DNA responsible for causing a disease; it could be correlated with any phenotype that has a genetic component. For example, pharmacogenetics involves determining how response to a given drug is affected by an individual's genotype; the goal is to be able to individualize drug treatments based on the patient's genotype (e.g., a liver enzyme cytochrome P450 breaks down certain drugs, and alterations in the gene encoding P450 affects how readily drugs are broken down; knowing this information affects optimal drug dosage). And since SNPs are the only part of a person's genotype that is relevant, it's accurate to say that drug treatments will be tailored to a person's SNP profile. Within 15 years, it is likely that patients will be able to take their personalized SNPchip with them when they visit their physician or pharmacist.
The ability to determine the genetic profile of both the born and unborn raises many ethical
issues. Who should be tested and are there any controls on which genetic tests should be available? Who has access to test results? How can those results be used? Who decides answers to these questions?
Problem Scenario and task:
Consider the scenario from the three perspectives given below.
Scenario 1) You are the VP of Human Resources for Wal-Mart and have been asked to: a)
investigate the genetic screening test offered by a company called 23andMe to determine its reliability, accuracy, and potential use in hiring/firing/health insurance decisions, and b)
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determine whether it is legal to use the test results in making hiring/firing/health insurance decisions. 23andMe advertised itself as a company with a "goal of democratizing genetic information by giving our customers access to even more of their SNP data through our next generation custom content, all at a lower price."
Task #1: Submit a position paper for the task above. Scenario 2) Your sister needs a job and has applied to work at a new Wal-Mart store. They have asked her to volunteer to be genetically screened by 23andMe, free of charge, as part of their job interview process. They haven't indicated it is required, but she assumes that if she doesn't agree, it will hurt her employment chances. She has exhausted all other legal source of revenue and this seems to be the only job opportunity in her community. She has come to you for advice.
Task #2: What advice would you give her (give your rationale behind each suggestion)?
Provide her a list of at least three pros and cons for being tested, with a counter argument for PBL 12 each item on the list. If you recommend she agree to be tested only on certain conditions, list those conditions (e.g., access to test results, specific traits to not be screened, etc.).
Scenario 3) You are a member of the NC Senate, which is currently considering a bill that would require genetic screening be performed on all a) prison inmates, b) people requesting welfare (including pregnant women without medical insurance who are receiving health care from a government-sponsored entity), c) and all newborns. Bill advocates indicate that this bill will help the state assess current and future health needs; bill proponents object on the grounds of violation of privacy rights.
Task #3: Submit a position paper to indicate whether this bill should be approved or not. Give three arguments-counter arguments for each position for each class of individuals to be
screened.
Indicate for which SNPs, if any, you would approve the bill in its current form?
Indicate for which SNPs, if any, you would approve the bill in a modified form (indicating the modification)?
Indicate for which SNPs would you oppose the bill in any form?
List two examples of currently mandated health screens required of some segment of the population.
Resources / Readings:
Web sites: 
NOTE:
Every student should email the course instructors any questions they would like answers to or problems they are having in developing their solution strategy, and how they would like the instructors to help (e.g., cover certain material in the next class, suggest a resource to obtain certain information).
Module #3 -Bioremediation of Oil Using a Suicidal GMO
Background
Oil serves as a primary energy source for humans, but it is also a major environmental pollutant. Oil sludge is present not just spill areas, but also in refineries and storage tanks. To clean up oil-contaminated areas, biological methods are often used, and such methods are often referred to as forms of "bioremediation." One challenge in biodegradation of oil compounds is that oil binds to soil particles and is highly hydrophobic, while the microbes that may metabolize oil compounds tend to grow in aqueous conditions. Use of surfactants has helped to blend and improve contact between the two, and microbial biosurfactants (surfactants produced by microbes) are generally preferred over synthetic ones.
The ideal bacterium to remediate oil contaminated areas would be one that both degrades hydrocarbons and produces biosurfactants. Some organisms have been genetically modified to contain or enhance both of these desired features, and one (an obligate aerobe) has emerged as a likely candidate for field testing. The concern with releasing such an ideal oil-metabolizing organism is that it might escape the contaminated release area and enter the environment "at large," where it could degrade other petroleum-based products and even invade oil reserves.
To minimize the potential for inadvertent GMO release, preliminary field tests of the GMO are being carried out in a storage tank. The microbe is added directly to a tank PBL 18
containing oil sludge, and neither is removed from the tank during the testing period.
However, even if the GMO succeeds in this testing phase, its full potential will not be realized unless the escape risk can be satisfactorily addressed.
One genetic engineering technique that could be considered for this application is the creation of an internal feedback mechanism whereby the cell could be configured such that it could not survive in the absence of oil. There are multiple examples of "suicidal" genetic systems in bacteria that have potential application in this scenario. Many of these systems exist in nature as part of a plasmid maintenance system.
Goal:
You are a university research team writing a proposal to EPA to allow testing of the oilconsuming, biosurfactants producing GMO. You will propose to test it under controlled conditions for future use in the field. The purpose of your research is to develop a molecular biology strategy to cause the oil-degrading, surfactant-producing bacteria to survive only when in the presence of oil. The strategy will be tested in aerated storage tank containments with the expectation that if the trials are successful, the microbe could ultimately be used at open bioremediation sites.
The research objectives are to: a) Identify gene(s) to use to make the oil-eating, biosurfactants producing GMO suicidal in the absence of some threshold of oil concentration. 
